HCCOs derived from end-stage tumours of cohort 5 (BM) mice expressed β-catenin, its downstream target GS and retained MYC overexpression as well as markers of proliferation (Ki-67) and differentiation (HNF4a), features that are shared with the corresponding primary tumour (Extended Data Fig. 10b). This evidence concerns the gene HNF4A and neoplasm.